

041380820

SENATE BILL NO. 325

Senate Amendments in [] — February 6, 2004

A BILL to amend and reenact § 54.1-3401 of the Code of Virginia and to amend the Code of Virginia by adding a section numbered 54.1-3455.1, relating to counterfeit drugs; the Drug Control Act; penalty.

Patron Prior to Engrossment—Senator Stolle

Referred to Committee on Education and Health

Be it enacted by the General Assembly of Virginia:

1. That § 54.1-3401 of the Code of Virginia is amended and reenacted, and that the Code of Virginia is amended by adding a section numbered 54.1-3455.1 as follows:

§ 54.1-3401. Definitions.

As used in this chapter, unless the context requires a different meaning:

"Administer" means the direct application of a controlled substance, whether by injection, inhalation, ingestion or any other means, to the body of a patient or research subject by (i) a practitioner or by his authorized agent and under his direction or (ii) the patient or research subject at the direction and in the presence of the practitioner.

"Advertisement" means all representations disseminated in any manner or by any means, other than by labeling, for the purpose of inducing, or which are likely to induce, directly or indirectly, the purchase of drugs or devices.

"Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser. It does not include a common or contract carrier, public warehouseman, or employee of the carrier or warehouseman.

"Anabolic steroid" means any drug or hormonal substance, chemically and pharmacologically related to testosterone, other than estrogens, progestins, and corticosteroids, that promotes muscle growth.

"Animal" means any nonhuman animate being endowed with the power of voluntary action.

"Automated drug dispensing system" means a mechanical or electronic system that performs operations or activities, other than compounding or administration, relating to pharmacy services, including the storage, dispensing, or distribution of drugs and the collection, control, and maintenance of all transaction information, to provide security and accountability for such drugs.

"Board" means the Board of Pharmacy.

"Bulk drug substance" means any substance that is represented for use, and that, when used in the compounding, manufacturing, processing, or packaging of a drug, becomes an active ingredient or a finished dosage form of the drug; however, "bulk drug substance" shall not include intermediates that are used in the synthesis of such substances.

"Change of ownership" of an existing entity permitted, registered or licensed by the Board means (i) the sale or transfer of all or substantially all of the assets of the entity or of any corporation that owns or controls the entity; (ii) the creation of a partnership by a sole proprietor, the dissolution of a partnership, or change in partnership composition; (iii) the acquisition or disposal of 50 percent or more of the outstanding shares of voting stock of a corporation owning the entity or of the parent corporation of a wholly owned subsidiary owning the entity, except that this shall not apply to any corporation the voting stock of which is actively traded on any securities exchange or in any over-the-counter market; (iv) the merger of a corporation owning the entity or of the parent corporation of a wholly-owned subsidiary owning the entity with another business or corporation; or (v) the expiration or forfeiture of a corporation's charter.

"Compounding" means the combining of two or more ingredients to fabricate such ingredients into a single preparation and includes the mixing, assembling, packaging, or labeling of a drug or device (i) by a pharmacist, or within a permitted pharmacy, pursuant to a valid prescription issued for a medicinal or therapeutic purpose in the context of a bona fide practitioner-patient-pharmacist relationship, or in expectation of receiving a valid prescription based on observed prescribing patterns; (ii) by or for a practitioner of medicine, osteopathy, podiatry, dentistry, or veterinary medicine as an incident to his administering or dispensing, if authorized to dispense, a controlled substance in the course of his professional practice; or (iii) for the purpose of, or as incident to, research, teaching, or chemical analysis and not for sale or for dispensing.

"Controlled substance" means a drug, substance or immediate precursor in Schedules I through VI of this chapter. The term shall not include distilled spirits, wine, malt beverages, or tobacco as those terms are defined or used in Title 3.1 or Title 4.1.

ENGROSSED

SB325E

59 *"Counterfeit drug" means a controlled substance that, without authorization, bears, is packaged in a*
60 *container or wrapper that bears, or is otherwise labeled to bear, the trademark, trade name, or other*
61 *identifying mark, imprint or device or any likeness thereof, of a drug manufacturer, processor, packer,*
62 *or distributor other than the manufacturer, processor, packer, or distributor who did in fact so*
63 *manufacture, process, pack or distribute such drug.*

64 "DEA" means the Drug Enforcement Administration, United States Department of Justice, or its
65 successor agency.

66 "Deliver" or "delivery" means the actual, constructive, or attempted transfer of any item regulated by
67 this chapter, whether or not there exists an agency relationship.

68 "Device" means instruments, apparatus, and contrivances, including their components, parts and
69 accessories, intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in
70 man or animals or to affect the structure or any function of the body of man or animals.

71 "Dialysis care technician" or "dialysis patient care technician" means an individual who is certified
72 by an organization approved by the Board of Health Professions pursuant to Chapter 27.01 (54.1-2729.1
73 et seq.) of this title and who, under the supervision of a licensed physician, nurse practitioner, physician
74 assistant or a registered nurse, assists in the care of patients undergoing renal dialysis treatments in a
75 Medicare-certified renal dialysis facility.

76 "Dialysis solution" means either the commercially available, unopened, sterile solutions whose
77 purpose is to be instilled into the peritoneal cavity during the medical procedure known as peritoneal
78 dialysis, or commercially available solutions whose purpose is to be used in the performance of
79 hemodialysis not to include any solutions administered to the patient intravenously.

80 "Dispense" means to deliver a drug to an ultimate user or research subject by or pursuant to the
81 lawful order of a practitioner, including the prescribing and administering, packaging, labeling or
82 compounding necessary to prepare the substance for that delivery.

83 "Dispenser" means a practitioner who dispenses.

84 "Distribute" means to deliver other than by administering or dispensing a controlled substance.

85 "Distributor" means a person who distributes.

86 "Drug" means (i) articles or substances recognized in the official United States Pharmacopoeia
87 National Formulary or official Homeopathic Pharmacopoeia of the United States, or any supplement to
88 any of them; (ii) articles or substances intended for use in the diagnosis, cure, mitigation, treatment or
89 prevention of disease in man or animals; (iii) articles or substances, other than food, intended to affect
90 the structure or any function of the body of man or animals; or (iv) articles or substances intended for
91 use as a component of any article specified in clause (i), (ii) or (iii). "Drug" does not include devices or
92 their components, parts or accessories.

93 "Drug product" means a specific drug in dosage form from a known source of manufacture, whether
94 by brand or therapeutically equivalent drug product name.

95 "Electronic transmission prescription" means any prescription, other than an oral or written
96 prescription or a prescription transmitted by facsimile machine, that is electronically transmitted directly
97 to a pharmacy without interception or intervention from a third party from a practitioner authorized to
98 prescribe or from one pharmacy to another pharmacy.

99 "Facsimile (FAX) prescription" means a written prescription or order, which is transmitted by an
100 electronic device over telephone lines that sends the exact image to the receiving pharmacy in hard copy
101 form.

102 "FDA" means the United States Food and Drug Administration.

103 "Hashish oil" means any oily extract containing one or more cannabinoids, but shall not include any
104 such extract with a tetrahydrocannabinol content of less than 12 percent by weight.

105 "Immediate precursor" means a substance which the Board of Pharmacy has found to be and by
106 regulation designates as being the principal compound commonly used or produced primarily for use,
107 and which is an immediate chemical intermediary used or likely to be used in the manufacture of a
108 controlled substance, the control of which is necessary to prevent, curtail, or limit manufacture.

109 "Label" means a display of written, printed or graphic matter upon the immediate container of any
110 article. A requirement made by or under authority of this chapter that any word, statement or other
111 information appear on the label shall not be considered to be complied with unless such word, statement
112 or other information also appears on the outside container or wrapper, if any, of the retail package of
113 such article, or is easily legible through the outside container or wrapper.

114 "Labeling" means all labels and other written, printed or graphic matter on an article or any of its
115 containers or wrappers, or accompanying such article.

116 "Manufacture" means the production, preparation, propagation, conversion or processing of any item
117 regulated by this chapter, either directly or indirectly by extraction from substances of natural origin, or
118 independently by means of chemical synthesis, or by a combination of extraction and chemical
119 synthesis, and includes any packaging or repackaging of the substance or labeling or relabeling of its
120 container. This term does not include compounding.

"Manufacturer" means every person who manufactures.

"Marijuana" means any part of a plant of the genus *Cannabis* whether growing or not, its seeds or resin; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds, or its resin. Marijuana shall not include any oily extract containing one or more cannabinoids unless such extract contains less than 12 percent of tetrahydrocannabinol by weight, nor shall marijuana include the mature stalks of such plant, fiber produced from such stalk, oil or cake made from the seeds of such plant, unless such stalks, fiber, oil or cake is combined with other parts of plants of the genus *Cannabis*.

"Medical equipment supplier" means any person, as defined in § 1-13.19, engaged in the delivery to the ultimate consumer, pursuant to the lawful order of a practitioner, of hypodermic syringes and needles, medicinal oxygen, Schedule VI controlled devices, those Schedule VI controlled substances with no medicinal properties which are used for the operation and cleaning of medical equipment and solutions for peritoneal dialysis.

"Narcotic drug" means any of the following, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (i) opium, opiates, and any salt, compound, derivative, or preparation of opium or opiates; (ii) any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in clause (i), but not including the isoquinoline alkaloids of opium; (iii) opium poppy and poppy straw; (iv) coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extraction of coca leaves which do not contain cocaine or ecgonine.

"New drug" means: (i) any drug, except a new animal drug or an animal feed bearing or containing a new animal drug, the composition of which is such that such drug is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling, except that such a drug not so recognized shall not be deemed to be a "new drug" if at any time prior to the enactment of this chapter it was subject to the Food and Drugs Act of June 30, 1906, as amended, and if at such time its labeling contained the same representations concerning the conditions of its use; or (ii) any drug, except a new animal drug or an animal feed bearing or containing a new animal drug, the composition of which is such that such drug, as a result of investigations to determine its safety and effectiveness for use under such conditions, has become so recognized, but which has not, otherwise than in such investigations, been used to a material extent or for a material time under such conditions.

"Nuclear medicine technologist" means an individual who holds a current certification with the American Registry of Radiological Technologists or the Nuclear Medicine Technology Certification Board.

"Official compendium" means the official United States Pharmacopoeia National Formulary, official Homeopathic Pharmacopoeia of the United States, or any supplement to any of them.

"Official written order" means an order written on a form provided for that purpose by the United States Drug Enforcement Administration, under any laws of the United States making provision therefor, if such order forms are authorized and required by federal law, and if no such order form is provided then on an official form provided for that purpose by the Board of Pharmacy.

"Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having such addiction-forming or addiction-sustaining liability. It does not include, unless specifically designated as controlled under Article 4 (§ 54.1-3437 et seq.) of this chapter, the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). It does include its racemic and levorotatory forms.

"Opium poppy" means the plant of the species *Papaver somniferum* L., except the seeds thereof.

"Original package" means the unbroken container or wrapping in which any drug or medicine is enclosed together with label and labeling, put up by or for the manufacturer, wholesaler, or distributor for use in the delivery or display of such article.

"Person" means both the plural and singular, as the case demands, and includes an individual, partnership, corporation, association, governmental agency, trust, or other institution or entity.

"Pharmacist-in-charge" means the person who, being licensed as a pharmacist, signs the application for a pharmacy permit and assumes full legal responsibility for the operation of the relevant pharmacy in a manner complying with the laws and regulations for the practice of pharmacy and the sale and dispensing of controlled substances; the "pharmacist-in-charge" shall personally supervise the pharmacy and the pharmacy's personnel as required by § 54.1-3432.

"Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.

182 "Practitioner" means a physician, dentist, licensed nurse practitioner pursuant to § 54.1-2957.01,
183 licensed physician assistant pursuant to § 54.1-2952.1, pharmacist pursuant to § 54.1-3300, TPA-certified
184 optometrist pursuant to Article 5 (§ 54.1-3222 et seq.) of Chapter 32 of this title, veterinarian, scientific
185 investigator, or other person licensed, registered or otherwise permitted to distribute, dispense, prescribe
186 and administer, or conduct research with respect to, a controlled substance in the course of professional
187 practice or research in this Commonwealth.

188 "Prescriber" means a practitioner who is authorized pursuant to §§ 54.1-3303 and 54.1-3408 to issue
189 a prescription.

190 "Prescription" means an order for drugs or medical supplies, written or signed or transmitted by word
191 of mouth, telephone, telegraph or other means of communication to a pharmacist by a duly licensed
192 physician, dentist, veterinarian or other practitioner, authorized by law to prescribe and administer such
193 drugs or medical supplies.

194 "Prescription drug" means any drug required by federal law or regulation to be dispensed only
195 pursuant to a prescription, including finished dosage forms and active ingredients subject to § 503 (b) of
196 the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 353 (b)).

197 "Production" or "produce" includes the manufacture, planting, cultivation, growing or harvesting of a
198 controlled substance or marijuana.

199 "Proprietary medicine" means a completely compounded nonprescription drug in its unbroken,
200 original package which does not contain any controlled substance or marijuana as defined in this chapter
201 and is not in itself poisonous, and which is sold, offered, promoted or advertised directly to the general
202 public by or under the authority of the manufacturer or primary distributor, under a trademark, trade
203 name or other trade symbol privately owned, and the labeling of which conforms to the requirements of
204 this chapter and applicable federal law. However, this definition shall not include a drug which is only
205 advertised or promoted professionally to licensed practitioners, a narcotic or drug containing a narcotic,
206 a drug which may be dispensed only upon prescription or the label of which bears substantially the
207 statement "Warning - may be habit-forming," or a drug intended for injection.

208 "Radiopharmaceutical" means any drug that exhibits spontaneous disintegration of unstable nuclei
209 with the emission of nuclear particles or photons and includes any non-radioactive reagent kit or
210 radionuclide generator that is intended to be used in the preparation of any such substance, but does not
211 include drugs such as carbon-containing compounds or potassium-containing salts that include trace
212 quantities of naturally occurring radionuclides. The term also includes any biological product that is
213 labeled with a radionuclide or intended solely to be labeled with a radionuclide.

214 "Sale" includes barter, exchange, or gift, or offer therefor, and each such transaction made by any
215 person, whether as an individual, proprietor, agent, servant or employee.

216 "Therapeutically equivalent drug products" means drug products that contain the same active
217 ingredients and are identical in strength or concentration, dosage form, and route of administration and
218 that are classified as being therapeutically equivalent by the United States Food and Drug Administration
219 pursuant to the definition of "therapeutically equivalent drug products" set forth in the most recent
220 edition of the Approved Drug Products with Therapeutic Equivalence Evaluations, otherwise known as
221 the "Orange Book."

222 "USP-NF" means the current edition of the United States Pharmacopeia-National Formulary.

223 "Warehouser" means any person, other than a wholesale distributor, engaged in the business of
224 selling or otherwise distributing prescription drugs or devices to any person who is not the ultimate user
225 or consumer. No person shall be subject to any state or local tax by reason of this definition.

226 "Wholesale distribution" means distribution of prescription drugs to persons other than consumers or
227 patients, subject to the exceptions set forth in § 54.1-3401.1.

228 "Wholesale distributor" means any person engaged in wholesale distribution of prescription drugs
229 including, but not limited to, manufacturers; repackers; own-label distributors; private-label distributors;
230 jobbers; brokers; warehouses, including manufacturers' and distributors' warehouses, chain drug
231 warehouses conducting wholesale distributions, and wholesale drug warehouses; independent wholesale
232 drug traders; and retail pharmacies conducting wholesale distributions. No person shall be subject to any
233 state or local tax as a wholesale merchant by reason of this definition.

234 The words "drugs" and "devices" as used in Chapter 33 (§ 54.1-3300 et seq.) of this title and in this
235 chapter shall not include surgical or dental instruments, physical therapy equipment, X-ray apparatus or
236 glasses or lenses for the eyes.

237 The terms "pharmacist," "pharmacy" and "practice of pharmacy" as used in this chapter shall be
238 defined as provided in Chapter 33 of this title unless the context requires a different meaning.

239 § 54.1-3455.1. Counterfeit drugs unlawful.

240 *It shall be unlawful to knowingly manufacture, sell, possess, distribute, dispense or facilitate the*
241 *distribution or dispensing of any counterfeit drug as defined in § 54.1-3401 [, knowing such drug to be*
242 *counterfeit] . Counterfeit drugs and all fixtures, equipment, materials and personal property used in*
243 *substantial connection with the manufacture, sale, possession, distribution, or dispensing or facilitating*

of distribution or dispensing of such counterfeit drugs shall be subject to the custody, seizure, forfeiture, disposal, and destruction provisions of Article 1 (§ 18.2-247 et seq.) of Chapter 7 of Title 18.2 and the requirements of this chapter and the regulations of the Board of Pharmacy in the same manner as would be applied to offenses relating to the controlled substance that the counterfeit drug purports to be.

Any person who knowingly manufactures, sells, possesses, distributes, dispenses or facilitates the distribution or dispensing of any counterfeit drug shall be, upon conviction, guilty of the penalty that would be applied for comparable activities relating to the controlled substance that the counterfeit drug purports to be in accordance with this chapter and Article 1 (§ 18.2-247 et seq.) of Chapter 7 of Title 18.2.

2. That the provisions of this act may result in a net increase in periods of imprisonment or commitment. Pursuant to § 30-19.1:4, the estimated amount of the necessary appropriation cannot be determined for periods of imprisonment in state adult correctional facilities and cannot be determined for periods of commitment to the custody of the Department of Juvenile Justice.

ENGROSSED

SB325E